An experimental treatment for people with neuroblastoma, an often-fatal nerve-cell disease, is being heralded as a "game-changer." The national study was led by Dr. Julie Park, professor of pediatrics at the University of Washington and pediatric oncologist at Seattle Children's.  It showed that patients with the disease who received two stem-cell transplants, rather than just one, are likely to have a better outcome.  

Park presented the results of the clinical trial June 5 in Chicago at the annual meeting of the American Society of Clinical Oncology.